A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DCIS / ductal carcinoma in situ

[Related PubMed/MEDLINE]
Total Number of Papers: 3850
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DCIS  (>> Co-occurring Abbreviation)
Long Form:   ductal carcinoma in situ
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Case Series of Malign Hyperechoic Breast Lesions. ---
2020 A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka. BCa, BLBC, TNBC
2020 A Multiscale Agent-Based Model of Ductal Carcinoma In Situ. ---
2020 A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction. BCT, PRO, TBR
2020 A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal Carcinoma In Situ, and Women Without Breast Cancer. EIBC, OR
2020 A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ. CA, CAS, LR, RT, VNPI
2020 A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. BCS
2020 A Single institution's randomized double-armed prospective study of lumpectomy margins with adjunctive use of the MarginProbe in nonpalpable breast cancers. BCS, IDC, ILC
2020 A Strategic Approach to Nipple-sparing Mastectomy Reconstruction with a Wide-based Inframammary Fold Flap. IMF
10  2020 ACCIDENTAL FINDING OF SYNCHRONOUS BILATERAL DUCTAL CARCINOMA IN SITU IN A YOUNG MAN REFERRED TO MASTECTOMY DUE TO GYNECOMASTIA - AND WHAT IF LIPOSUCTION HAVE BEEN USED? CASE REPORT. ---
11  2020 Adoption of SSO-ASTRO Margin Guidelines for Ductal Carcinoma in Situ: What Is the Impact on Use of Additional Surgery? BCS, WBRT
12  2020 An update on the management of breast atypical ductal hyperplasia. ADH
13  2020 Analysis of active surveillance as a treatment modality in ductal carcinoma in situ. AS
14  2020 Analysis of key genes and pathways in breast ductal carcinoma in situ. BC, DEGs, FABP4, LEP, LPL, PPARG, PPI
15  2020 Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines? ACS-NSQIP, ALN, ALND, BCS, SLNB
16  2020 Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds. IDC
17  2020 ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. ADH, ANGPTL4, DFS, IDC, OS
18  2020 Annual Trends in Ultrasonography-Guided 14-Gauge Core Needle Biopsy for Breast Lesions. BI-RADS, CI, CNB, OR, US
19  2020 Application of Contrast-Enhanced Ultrasound in the Diagnosis of Ductal Carcinoma In Situ: Analysis of 127 Cases. CEUS
20  2020 Application of magnetic resonance computer-aided diagnosis for preoperatively determining invasive disease in ultrasonography-guided core needle biopsy-proven ductal carcinoma in situ. CAD, CI, DCE-MRI, OR, US
21  2020 ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS). ---
22  2020 Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. ---
23  2020 Associated Features with Non-Sentinel Lymph Node Involvement in Early Stage Breast Cancer Patients who Have Positive Macrometastatic Sentinel Lymph Node. BC, cALND, ECE, LNs, NSLNI, SLN
24  2020 Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. NET, OS
25  2020 Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. SEER
26  2020 Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma. ABE, BCa, IDC, IHC
27  2020 Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study. CIs, ORs, SEER
28  2020 Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials. ADH, COMET
29  2020 Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision. ADH, DCE
30  2020 Author Correction: DNA methylation landscape of triple-negative ductal carcinoma in situ (DCIS) progressing to the invasive stage in canine breast cancer. ---
31  2020 BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression. BCL9, MIND, PS-727-STAT3
32  2020 Benign Breast Intraductal Papillomas Without Atypia at Core Needle Biopsies: Is Surgical Excision Necessary? CNB, IDPs
33  2020 Breast Biopsy During Post-treatment Surveillance of Screen-Detected Breast Cancer Patients Yields High Rates of Benign Findings. BCS, CI
34  2020 Breast Cancer Screening Trials: Endpoints and Over-diagnosis. DBT, MRI
35  2020 Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. CPX, CPXZn, NPs, NSs
36  2020 Breast magnetic resonance imaging for estimation of the tumour extent in patients with pure ductal carcinoma in situ: Comparison between full diagnostic and abbreviated protocols. AP, BPE, FDP
37  2020 Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? dbPET, FOV, Lugo, Spain
38  2020 Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment. CIS, LN, SA
39  2020 CD133 expressionand clinicopathologic significance in benign and malignant breast lesions. ADH
40  2020 CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ. AUC, CI, CNB, GMM, IBC
41  2020 Characteristics of ultrasonographic images of ductal carcinoma in situ with abnormalities of the ducts. JABTS
42  2020 Characterization of breast lesions using diffusion kurtosis model-based imaging: An initial experience. ADC, AUC, DWI, IDC, MD, MK, ROC
43  2020 Clinic-Pathological Features of Breast Ductal Carcinoma in Situ with Micro-Invasion. DCIS-MI
44  2020 Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. DBT, MRI, PPV
45  2020 Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. DBT, MRI, PPV
46  2020 Comparison of BSGI, MRI, mammography, and ultrasound for the diagnosis of breast lesions and their correlations with specific molecular subtypes in Chinese women. BSGI, LNR, MRI
47  2020 Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. IBC
48  2020 Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer. ER, HER2, MDT, NHS, NPI, ODX, RS, SLNB
49  2020 Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ. IBE, RT
50  2020 Cost-effectiveness of preoperative magnetic resonance imaging to optimize surgery in ductal carcinoma in situ of the breast. MRI
51  2020 Could ultrasound-guided cryoablation be used to manage "low-risk" DCIS?: a feasibility case report. ---
52  2020 Decreased Nek9 expression correlates with aggressive behaviour and predicts unfavourable prognosis in breast cancer. ---
53  2020 Development of Robotic Mastectomy Using a Single-Port Surgical Robot System. ---
54  2020 Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy. ---
55  2020 Differences in pathologic characteristics between ductal carcinoma in situ (DCIS), DCIS with microinvasion and DCIS with invasive ductal carcinoma. DCIS-Mi
56  2020 DNA methylation landscape of triple-negative ductal carcinoma in situ (DCIS) progressing to the invasive stage in canine breast cancer. ADH, TN-DCIS, TNBC
57  2020 Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma? AS
58  2020 Does a Close Surgical Margin for Ductal Carcinoma In Situ Associated with Invasive Breast Carcinoma Affect Breast Cancer Recurrence? BCT, IBC, IBTR
59  2020 Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good? ALND, HG-DCIS, SLNB
60  2020 Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. ---
61  2020 Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma. MRI
62  2020 Ductal carcinoma in situ (DCIS): The importance of patient-reported outcomes (PRO). PRO, PROs, QOL
63  2020 Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary? CNB, SNB
64  2020 Ductal Carcinoma In Situ Biology, Language, and Active Surveillance: A Survey of Breast Radiologists' Knowledge and Opinions. ---
65  2020 Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors. IBC, MRI
66  2020 Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment. BCS, BCSM, HER2, HoR, OS, SEER, TN
67  2020 Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade. DBT, DM
68  2020 Ductal Carcinoma In Situ Progression in Dog Model of Breast Cancer. ADH, EMT
69  2020 Ductal Carcinoma In Situ Underestimation of Microcalcifications Only by Stereotactic Vacuum-Assisted Breast Biopsy: A New Predictor of Specimens without Microcalcifications. IDC, VABB
70  2020 Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. ---
71  2020 Effect of implementing digital breast tomosynthesis (DBT) instead of mammography on population screening outcomes including interval cancer rates: Results of the Trento DBT pilot evaluation. BC, DBT, DM, RR
72  2020 Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma. IDC, MRI
73  2020 Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer. TAMX
74  2020 Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. BCS, IBC, IBTR, OS, PFS, WBRT
75  2020 Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis. ANA, BCS, CBCR, CBCR-INV, EFS, IBCR, IBCR-INV, RT, TAM
76  2020 Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort. CI, CPS-II, HR, IDBC
77  2020 Essential role of STAT5a in DCIS formation and invasion following estrogen treatment. BCa, Cav-1, IBC, MMP-9, STAT5a
78  2020 Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data. ---
79  2020 Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. ER, PgR
80  2020 Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. ER, PgR
81  2020 Evaluating the role of sentinel lymph node biopsy in patients with DCIS treated with breast conserving surgery. BCS, NCDB, SLNB
82  2020 Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression. ---
83  2020 Evaluation of Long-Term Satisfaction with Breast Surgery in Patients Treated for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. BCS, CI, OR, QOL
84  2020 Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression. IDC, MMP9
85  2020 Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast. CAIX, DCIS-AIC, GLUT1, HIF-1alpha, IC
86  2020 Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ. CA15-3, CNB, IDC, OR, PLR, VAB
87  2020 Flat epithelial atypia on core needle biopsy does not always mandate excisional biopsy. AH, CNB, FEA, IDC, LCIS
88  2020 Fractal Analysis Method for the Complexity of Cell Cluster Staining on Breast FNAB. FA, FNAB, HCG, IBC-NST
89  2020 Fractionation in adjuvant radiotherapy for invasive breast cancer and ductal carcinoma in situ in Ontario, Canada from 2009 to 2015. BCS, HFRT, ICES
90  2020 Gas6 expression is reduced in advanced breast cancers. Gas6
91  2020 Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. GCT-ST, GCTB, Histone H3.3
92  2020 Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports. ODS, ORs
93  2020 HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence. IDC, iIDC
94  2020 High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. ER, IBC
95  2020 Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast. CI, DFS, HER2, HR, PD-1, PD-L1, PR, TILs
96  2020 Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. DFS, HER2, PR
97  2020 Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. DBCG, fr
98  2020 Identification and transfer of spatial transcriptomics signatures for cancer diagnosis. IDC, ST
99  2020 Identification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysis. DEGs, GEO, SNVs, TF
100  2020 Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians. PCC